Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016

por Ylescas‐Soria, Jimena, de la Torre‐Lujan, Alfredo H., Herrera, Luis A., Miranda, Daniela, Grimaldo, Flavio, Rivas, Silvia, Cervera, Eduardo, Meneses‐García, Abelardo, Leon-Sarmiento, Fidias E., Prada, Diddier
Publicado 2019

Large‐scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML

por Fabian‐Morales, Eunice, Vallejo‐Escamilla, David, Gudiño, Adriana, Rodríguez, Alfredo, González‐Barrios, Rodrigo, Rodríguez Torres, Yameli L., Castro Hernández, Clementina, de la Torre‐Luján, Alfredo H., Oliva‐Rico, Diego A., Ornelas Guzmán, Erandhi C., López Saavedra, Alejandro, Frias, Sara, Herrera, Luis A.
Publicado 2021